Date: 2012-02-16
Type of information: R&D agreement
Compound: nano-enabled intranasal formulation of teriparatide
Company: Critical Pharmaceuticals (UK) The University of Nottingham (UK)
Therapeutic area: Bone diseases
Type agreement: R&D
Action mechanism:
Disease: osteoporosis
Details: Critical Pharmaceuticals and The University of Nottingham have announced a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. The consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare. Critical Pharmaceuticals CriticalSorb™ nanotechnology is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs.
Financial terms:
Latest news:
